| 21251937 |
Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib
Zhang, GC,
Wang, Z,
Ye, T,
Friedman, SL,
Lam, RWC,
Liu, Y,
Zhang, H,
Kwong, SQ,
Li, FR,
Lui, ELH
|
J. Hepatol. |
2011 |
| 29408302 |
The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
Roskoski, R
|
Pharmacol. Res. |
2018 |
| 16436588 |
Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)
Wu, J,
Chen, Z,
Lee, FY,
Bhalla, KN
|
Mol. Pharmacol. |
2006 |
| 18559524 |
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Rettig, WJ,
Tontsch-Grunt, U,
Hilberg, F,
Garin-Chesa, P,
Krssak, M,
Quant, J,
Heckel, A,
Zoephel, A,
Kautschitsch, S,
Roth, GJ,
Sommergruber, W,
Bader, G
|
Cancer Res. |
2008 |
| 17943726 |
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Asada, M,
Yamamoto, Y,
Matsui, J,
Tsuruoka, A,
Uenaka, T,
Funahashi, Y,
Wakabayashi, T,
Watanabe, T
|
Int J Cancer |
2008 |
| 31085175 |
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Hood, MM,
Gupta, A,
Su, Y,
Ensinger, CL,
Caldwell, TM,
Bulfer, SL,
Heinrich, MC,
Al-Ani, G,
Ahn, YM,
Patt, WC,
Janku, F,
Turner, BA,
Ruiz-Soto, R,
Leary, CB,
Abdul Razak, AR,
Yates, K,
Town, A,
Rosen, O,
Wise, SC,
Vogeti, L,
Telikepalli, H,
Rutkoski, TJ,
Vogeti, S,
Smith, BD,
Flynn, DL,
Chun, L,
Lu, WP,
Kaufman, MD,
McKinley, A
|
Cancer Cell |
2019 |
| 12369853 |
BAY 43-9006: preclinical data
Wilhelm, S,
Chien, DS
|
Curr. Pharm. Des. |
2002 |
| 15615512 |
Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
Schmidt, RJ,
Barrish, JC,
Castaneda, S,
Tokarski, J,
Kan, D,
Marathe, P,
Kamath, A,
Schieven, GL,
Lee, FY,
Norris, D,
Doweyko, AM,
Chen, P,
Wityak, J,
Johnston, K,
Pitt, S,
Lombardo, LJ,
Cornelius, LA,
Fairchild, C,
Klei, H,
Hunt, JT,
Das, J,
Inigo, I,
Pang, S,
Borzilleri, RM,
Wen, ML,
Behnia, K,
Peterson, R
|
J. Med. Chem. |
2004 |
| 12538485 |
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
Sukbuntherng, J,
Tang, C,
Lee, LB,
Sun, L,
Haznedar, JO,
Cherrington, JM,
McMahon, G,
Louie, SG,
Ngai, TJ,
Abrams, TJ,
Carver, J,
Chan, E,
Schreck, RE,
Laird, AD,
Shirazian, S,
Miller, T,
Blake, RA,
Murray, LJ,
Li, G,
Xin, X,
Moss, KG,
Christensen, JG,
Mendel, DB
|
Clin. Cancer Res. |
2003 |
| 29263244 |
Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases
Le, AT,
Baum, A,
Tontsch-Grunt, U,
Hilberg, F,
Haslinger, C,
Garin-Chesa, P,
Gianni, D,
Doebele, RC,
Kraut, N,
Lieb, S,
Voss, T
|
J. Pharmacol. Exp. Ther. |
2018 |
| 17367763 |
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R
|
Biochem. Biophys. Res. Commun. |
2007 |
| 29137923 |
The PDGF/PDGFR pathway as a drug target
Lennartsson, J,
Papadopoulos, N
|
Mol. Aspects Med. |
2018 |
| 16474853 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment
Strumberg, D
|
Drugs Today |
2005 |
